Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 9/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.49 |
| ▸ | F10 | P00742 | 5/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | SDHB | P21912 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8632872 | 0.88 | PTGS2 (0.39) | PTGS2PTGS1F10CA12CA1 | |
| SCHEMBL8632879 | 0.88 | PTGS2 (0.58) | PTGS2PTGS1F10F2 | |
| SCHEMBL8629412 | 0.87 | PTGS2 (0.38) | PTGS2PTGS1F10CA12CA1 | |
| SCHEMBL8630025 | 0.87 | PTGS2 (0.58) | PTGS2PTGS1F10CA12CA1 | |
| SCHEMBL8631752 | 0.86 | PTGS2 (0.37) | PTGS2PTGS1F10CA12CA1 | |
| SCHEMBL8629101 | 0.86 | F10 (0.39) | PTGS2PTGS1F10CA12CA1 | |
| SCHEMBL8632851 | 0.85 | PTGS2 (0.42) | PTGS2PTGS1F10CA12CA1 | |
| SCHEMBL8629123 | 0.85 | PTGS2 (0.70) | PTGS2PTGS1F10 | |
| SCHEMBL7780842 | 0.85 | PTGS2 (0.70) | PTGS2PTGS1CA12CA1CA2 | |
| SCHEMBL8488736 | 0.85 | PTGS2 (0.55) | PTGS2PTGS1F10F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5756530-A | NON-STEROIDAL ANTIINFLAMMATORY AGENTS WITH REDUCED SIDE EFFECTS | G. D. SEARLE & CO. (US) | 1998-05-26 | — | — | US | disclosed |